603168.SH
Zhejiang Shapuaisi Pharmaceutical Co. Ltd.
SSE · Healthcare · Medical - Pharmaceuticals · CN
CNY 5.54
−0.72%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 459.6M | 462.8M | 484.0M | 645.0M | 549.5M |
| Cost of Revenue | 255.8M | 250.1M | 246.1M | 283.9M | 227.9M |
| Gross Profit | 203.7M | 212.7M | 237.8M | 361.0M | 321.6M |
| Operating Expenses | |||||
| R&D Expense | 20.6M | 25.2M | 57.6M | 64.4M | 59.6M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 100.0M | 102.1M | 132.3M | 136.3M | 117.0M |
| Selling & Marketing Expense | 87.8M | 91.6M | 96.9M | 135.3M | 93.3M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 222.6M | 235.1M | 299.9M | 345.3M | 274.6M |
| Cost and Expenses | 478.4M | 485.2M | 546.0M | 629.2M | 502.5M |
| Operating Income (EBIT) | (274.0M) | (239.3M) | (111.9M) | 22.0M | 55.6M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (274.8M) | (239.9M) | (115.6M) | 33.1M | 54.0M |
| Income Tax Expense | (1.1M) | (1.2M) | 5.9M | 8.0M | 9.3M |
| Bottom Line | |||||
| Net Income | (273.7M) | (238.7M) | (123.4M) | 25.4M | 44.8M |
| Earnings from Cont. Ops | (273.7M) | (238.7M) | (121.5M) | 25.1M | 45.8M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (273.7M) | (238.7M) | (123.4M) | 25.4M | 44.8M |
| Per Share | |||||
| Basic EPS | (CN¥0.73) | (CN¥0.64) | (CN¥0.33) | CN¥0.07 | CN¥0.14 |
| Diluted EPS | (CN¥0.73) | (CN¥0.64) | (CN¥0.33) | CN¥0.07 | CN¥0.14 |
| Revenue Per Share | CN¥1.23 | CN¥1.24 | CN¥1.29 | CN¥1.78 | CN¥1.72 |
| Shares | |||||
| Basic Shares Outstanding | 372.9M | 373.0M | 374.1M | 363.0M | 319.7M |
| Diluted Shares Outstanding | 372.9M | 373.0M | 374.1M | 363.0M | 319.7M |
| Profitability Metrics | |||||
| EBITDA | — | (173.3M) | (46.7M) | 88.5M | 116.2M |
| D&A | — | 66.0M | 65.3M | 66.4M | 60.6M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026